Opinion|Videos|November 13, 2026

DESTINY-Breast11: T-DXd Moves Into the Neoadjuvant HER2-Positive Setting

We’re going to transition a bit to your space, but we’re also going to be talking about the curative-intent setting.

Sun: I completely agree. We’re going to transition a bit to your space, but we’re also going to be talking about the curative-intent setting. So there will certainly be some parallels in how we integrate new and novel therapies into our armamentarium for patients.

Jahan: Thank you. Today I’ll discuss DESTINY-Breast11. This study integrated the antibody–drug conjugate trastuzumab deruxtecan (T-DXd) into the neoadjuvant setting for HER2-positive breast cancer. For context, in stage II and stage III HER2-positive breast cancer, we have traditionally used chemotherapy plus dual anti-HER2 antibodies — trastuzumab and pertuzumab. In the United States we predominantly use TCHP (docetaxel, carboplatin, trastuzumab, and pertuzumab). In Europe, practice is slightly different — dose-dense doxorubicin plus cyclophosphamide (AC) followed by a taxane with trastuzumab and pertuzumab (THP). Both are acceptable regimens, but we have always wanted to improve outcomes.

Jahan: DESTINY-Breast11 was a three-arm study. One arm was T-DXd monotherapy for 8 cycles. The second arm was T-DXd for 4 cycles followed by THP (taxane + trastuzumab + pertuzumab) for 4 cycles. The third arm was standard of care — dose-dense AC followed by THP — as commonly used in Europe. The primary outcome was pathologic complete response (pCR), which is a well-established endpoint in neoadjuvant breast cancer because patients who achieve pCR tend to do very well long term.

Jahan: The T-DXd monotherapy arm (8 cycles) was closed early because the pCR rate was lower than in the other two arms. So the comparison that remains is T-DXd followed by THP versus dose-dense AC followed by THP. The T-DXd–based regimen achieved a pCR rate of approximately 67%, versus approximately 53% in the dose-dense AC arm. That is a paradigm-shifting result — it is the first ADC–chemotherapy strategy to show significant improvement in pCR in this setting. It also tells us that even with a very active drug like T-DXd, single-agent therapy is not enough; we likely still need multi-agent treatment in high-risk HER2-positive early breast cancer.

Jahan: The regimen was quite well tolerated. The toxicity we always watch for with T-DXd is interstitial lung disease (ILD). The rate in the T-DXd + THP arm was approximately 4.4%, and in the standard-of-care dose-dense AC arm it was approximately 5.1% — so very comparable. The benefit was seen in both hormone receptor–positive and hormone receptor–negative disease. Hormone receptor–positive, HER2-positive tumors typically show lower pCR rates than hormone receptor–negative, HER2-positive tumors, but the delta in response was very similar between the two groups — more than 9% in the hormone receptor–positive subgroup and closer to 11% in the hormone receptor–negative subgroup. Both lymph node–positive and lymph node–negative disease showed improvement in pCR. The regimen recently received FDA approval, and we are actively discussing it with patients.

Sun: I’m curious — pCR was the primary outcome in this study. Any thoughts on whether that was the appropriate endpoint, and how meaningful it is when many patients think in terms of disease-free survival or more time-to-event outcomes?

Jahan: It is an appropriate and important endpoint in breast cancer for several reasons. In many studies over the past decade, pCR has been a strong predictive and prognostic marker for long-term outcomes. The other factor is that, fortunately, patients with HER2-positive breast cancer now have excellent overall survival because of the number of effective therapies available. That means it takes much longer follow-up to see a definitive overall survival signal. For us, pCR is a very useful early endpoint for new treatment strategies.

Sun: You mentioned that in the United States many clinicians prefer TCHP, as opposed to the European regimen used as the control arm in this trial. If you’re sitting in clinic next Monday, how do you decide between TCHP and this new T-DXd–based regimen when the two were not directly compared?

Jahan: TCHP pCR rates are quite comparable to dose-dense AC–THP. TCHP is given every 3 weeks for 6 cycles, so the overall duration of treatment is somewhat shorter. One of the major factors in my decision is how high risk the patient is. DESTINY-Breast11 enrolled very high-risk patients — they had to be lymph node–positive, or T3 or T4. So for very high-risk patients, we are preferentially selecting T-DXd followed by THP.

Jahan: Another important point: T-DXd also has an approval in the adjuvant setting, but there it is given for 14 cycles, whereas in the neoadjuvant setting under DESTINY-Breast11 it is given for only 4 cycles. Many clinicians prefer the 4-cycle neoadjuvant exposure because the side-effect burden is lower — the ILD rate was 4.4% with 4 cycles neoadjuvantly, compared with more than 10% with the 14-cycle adjuvant regimen. That matters.

Jahan: One unanswered question in this setting is what to do for patients who still have residual disease after a DESTINY-Breast11–style regimen. Do we treat them again with T-DXd, or with the current adjuvant standard of trastuzumab emtansine (T-DM1)? We don’t yet have high-quality data to answer that, and the field is working through it.

Sun: That is a great segue to say we certainly need more studies in both of these disease groups in the curative-intent setting. That’s the essence of communicating Between the Lines — taking the data and making it clear, honest, and useful. Thanks for watching Between the Lines.


Related to this article